MedPath

SCOTTSDALE HEALTHCARE

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:3

Trial Phases

1 Phases

Early Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (100.0%)

An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer

Completed
Conditions
Advanced Cancer
First Posted Date
2011-09-29
Last Posted Date
2014-05-14
Lead Sponsor
Scottsdale Healthcare
Target Recruit Count
11
Registration Number
NCT01443390
Locations
🇺🇸

Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, Scottsdale, Arizona, United States

Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening

Terminated
Conditions
Non-Small Cell Lung Cancer
First Posted Date
2008-02-05
Last Posted Date
2008-07-17
Lead Sponsor
Scottsdale Healthcare
Target Recruit Count
40
Registration Number
NCT00607425

Propofol Sedation Study

Completed
Conditions
Anesthesia
First Posted Date
2008-01-18
Last Posted Date
2013-12-03
Lead Sponsor
Scottsdale Healthcare
Target Recruit Count
57
Registration Number
NCT00597740
Locations
🇺🇸

Scottsdale Healthcare Osborn, Scottsdale, Arizona, United States

Molecular Profiling Protocol (SCRI-CA-001)

Early Phase 1
Completed
Conditions
Refractory Cancer
First Posted Date
2007-09-17
Last Posted Date
2009-07-10
Lead Sponsor
Scottsdale Healthcare
Target Recruit Count
86
Registration Number
NCT00530192
Locations
🇺🇸

Oncology Specialties, Huntsville, Alabama, United States

🇺🇸

TGen Clinical Research Services, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic, Scottsdale, Arizona, United States

and more 6 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.